Evaluation of the therapeutic effect of new hypoglycemic drugs on patients with heart failure with reduced ejection fraction and type 2 diabetes: a systematic review and network meta-analysis
Abstract
Background: This systematic review and network meta-analysis synthesizes evidence from randomized controlled trials (RCTs) investigating three novel glucose-lowering therapies in patients with coexisting heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus(T2DM). We evaluated composite cardiovascular outcomes in this high-risk cohort.
Methods: A comprehensive literature search without language restrictions was performed across PubMed, EMBASE, and the Cochrane Library from inception to September 1, 2025. The network meta-analysis assessed the following endpoints: Composite of cardiovascular death and heart failure hospitalization; Hospitalization for heart failure; Left ventricular ejection fraction (LVEF); N-terminal pro-B-type natriuretic peptide (NT-proBNP); Estimated glomerular filtration rate (eGFR); Glycated hemoglobin (HbA1c). Quality appraisal of included RCTs using the Cochrane Risk of Bias Tool 2.0 (ROB2) and Confidence in Network Meta-Analysis (CINeMA) for grading evidence certainty. The study protocol was prospectively registered with PROSPERO (CRD420251269519).
Results: The final analysis pooled data from 16 randomized trials encompassing 14,710 patients. For the composite of cardiovascular death or hospitalization for heart failure, Sotagliflozin demonstrated the most substantial risk reduction (OR = 0.49; 95% CI 0.39, 0.62). This agent also showed significant efficacy against heart failure readmission (OR = 0.53; 95% CI 0.45, 0.63).…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 14,710 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.